ATR12-351 not checked

Azitra Inc. · ATR-12

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis”In the company’s words, NCT06137157 on ClinicalTrials.gov
Tested for
Netherton Syndrome
Main trialPhase 1
“The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.”In the company’s words, NCT06137157 on ClinicalTrials.gov
Other names
ATR-12

Other drugs for Netherton Syndrome

All 2 drugs for Netherton Syndrome

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 7 Jul 2026 Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ATR12-351

Following is part of Solo: you see every change to ATR12-351 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in